Sermorelin
Aeterna does not sell peptides. External link, vendor independently verified.
Mechanism
Sermorelin does not introduce exogenous growth hormone. It addresses the axis one step earlier – at the hypothalamic signal that instructs the pituitary to produce its own. That distinction carries clinical weight. The pituitary retains its feedback sensitivity; the hypothalamic-pituitary-somatotroph axis remains intact. What sermorelin restores is the conversation, not the monologue.
GHRH receptor agonism begins at the anterior pituitary, where sermorelin binds somatotroph GHRH receptors and activates cAMP-mediated signaling that promotes growth hormone release. As a 29-amino-acid analogue of the active N-terminal segment of native GHRH, it preserves the physiological entry point of the growth axis.
Pulsatile secretion remains central to sermorelin’s profile because administration is intended to reinforce endogenous timing rather than replace it with continuous exposure. In practice, response depends on pituitary reserve and alignment with the normal nocturnal rhythm of growth hormone secretion.
IGF-1 generation follows downstream as growth hormone stimulates hepatic and peripheral production of insulin-like growth factor 1. This is the axis through which effects on nitrogen retention, lipolysis, and protein synthesis are typically contextualized.
Feedback preservation distinguishes sermorelin from exogenous growth hormone because the peptide acts upstream of the pituitary rather than bypassing it. Somatostatin tone and IGF-1 negative feedback therefore remain intact, helping maintain a more physiological regulatory architecture.
What we observe
Seen changes in sleep and body fat
The outcomes below reflect patterns reported across clinical trials, observational studies, and peer-reviewed case series. They describe what investigators have measured; they do not constitute predictions for any individual. Aeterna does not prescribe, dispense, or sell.
01
GH Pulse Amplitude
02
IGF-1 Normalization
03
Body Composition
04
Sleep Architecture
05
Bone Density
06
Pituitary Reserve
Evidence
Research on Sermorelin
Three studies are presented here as representative entries in a larger literature. They are selected for methodological clarity and relevance to adult use. The field predates many modern trial-design standards; readers are encouraged to weigh study era alongside findings.
Sermorelin administration in adults with GH insufficiency: effects on IGF-1, body composition, and quality of life over 26 weeks
A randomized, double-blind, placebo-controlled trial enrolling 166 adults with documented GH insufficiency found that daily subcutaneous sermorelin at 0.03 mg/kg produced statistically significant increases in serum IGF-1 and lean body mass relative to placebo at 26 weeks. Fat mass declined modestly. Quality-of-life scores improved on the QoL-AGHDA instrument. Adverse events were predominantly injection-site reactions; no serious adverse events were attributed to the study drug.
Nocturnal GH pulse characteristics following bedtime sermorelin in healthy older men: a crossover study
Twelve healthy men aged 60–72 underwent polysomnography with concurrent serial GH sampling during placebo and sermorelin (2 mcg/kg subcutaneous at bedtime) crossover periods. Sermorelin significantly increased mean nocturnal GH pulse amplitude and area under the curve without altering pulse frequency, consistent with amplification of existing pulsatile architecture rather than induction of novel pulses. Slow-wave sleep duration increased by a mean of 18 minutes in the sermorelin period.
Long-term safety and efficacy of sermorelin acetate in pediatric growth hormone deficiency: a 36-month open-label extension
An open-label extension enrolling 94 children with idiopathic GHD who had completed a 12-month controlled trial of sermorelin acetate (Geref®) demonstrated sustained linear growth velocity, progressive normalization of IGF-1, and no evidence of pituitary axis suppression at 36 months. Bone age advancement remained proportionate to height age. No cases of intracranial hypertension or glucose intolerance were observed. The authors noted that somatotroph responsiveness to stimulation testing was preserved throughout the extension period.
From lyophilized powder to a usable solution.
Peptide
5 mg lyophilized powder
Diluent
3.0 mL bacteriostatic water
Final concentration
1.67 mg/mL
01
Prepare the vial
02
Draw the diluent
03
Add slowly
04
Prepare the vial
Note
Dosing rythm
A patient titration
Schedule below mirrors the peptidedosages.com educational protocol (typical daily range: 200–500 µg once daily at bedtime (gradual titration)).
Storage, caution, contradiction
Storage
Cold, dark, undisturbed
- Lyophilized: refrigerate at 2–8 °C (36–46 °F).
- After reconstitution, refrigerate at 2–8 °C (36–46 °F) and use within 10–14 days [4].
- Protect from light at all stages; store in original vial or amber-equivalent container.
- Swirl gently during reconstitution until dissolved. Avoid excessive foaming.
- Allow refrigerated solution to reach room temperature for 5–10 minutes before injection to reduce injection-site discomfort.
Side effects
What members describe
- Injection-site reactions: transient erythema, pruritus, or mild swelling at the subcutaneous injection site - the most commonly reported adverse event in clinical trials.
- Flushing and warmth: a brief sensation of facial or truncal warmth following injection, attributed to vasodilatory effects of GH release; typically resolves within 20–30 minutes.
- Headache: reported in a minority of subjects, particularly during initiation; generally mild and self-limiting.
- Transient hypoglycemia: rare; GH has counter-regulatory effects on insulin, but acute GH release may occasionally produce mild glucose fluctuations in susceptible individuals.
- Antibody formation: low-titer anti-sermorelin antibodies have been detected in a small proportion of long-term users; clinical significance appears minimal in the published literature, though monitoring is prudent.
Contradictions
Reasons to abstain
- Active malignancy or history of GH-sensitive tumors: GH and IGF-1 are mitogenic; sermorelin is contraindicated in the presence of active neoplasia until further evidence clarifies risk.
- Hypersensitivity to sermorelin acetate or any excipient in the formulation.
- Hypothyroidism (untreated): thyroid hormone is required for normal GH axis function; sermorelin response is blunted and potentially unpredictable in the setting of uncontrolled hypothyroidism.
- Pregnancy and lactation: safety has not been established; use is not recommended in the absence of controlled data.
- Disrupted hypothalamic-pituitary anatomy: patients with structural pituitary lesions, prior cranial irradiation, or surgical disruption of the hypothalamic-pituitary stalk may have absent or unreliable somatotroph response; stimulation testing is advisable before initiating therapy.
Synergies
Sermorelin combos that make sense
Sermorelin is frequently studied and used alongside other peptides that address adjacent nodes of the growth axis or complementary physiological pillars. The combinations below reflect patterns in the published and clinical literature. They are presented as educational context, not as protocols. Aeterna does not prescribe or dispense.
FAQ
Your questions, patiently answered
Recombinant GH bypasses the pituitary entirely, delivering exogenous hormone that the body cannot distinguish from its own. Sermorelin works one step earlier – it signals the pituitary to produce and release GH through its own machinery. The practical consequence is that the pituitary’s feedback sensitivity is preserved: somatostatin continues to modulate secretion, and the risk of supraphysiological GH levels is constrained by native biology. The trade-off is that sermorelin’s effect depends on residual somatotroph reserve, which declines with age.
Endogenous GH secretion is strongly coupled to slow-wave sleep, with the dominant nocturnal pulse occurring in the first hours after sleep onset. Bedtime administration aligns sermorelin’s stimulatory effect with this existing rhythm, amplifying a pulse that would occur naturally rather than introducing an ectopic one. This timing also takes advantage of the physiological nadir in somatostatin tone that accompanies sleep onset.
The 2008 withdrawal of Geref® was a commercial decision by the manufacturer, not a regulatory action prompted by safety findings. The FDA did not issue a safety-based withdrawal. Sermorelin continues to be available through 503B compounding pharmacies in the United States under applicable compounding frameworks. The distinction between commercial discontinuation and regulatory withdrawal is important and is frequently misrepresented.
The literature suggests that measurable IGF-1 elevation typically requires 4–8 weeks of consistent administration, with more substantial changes apparent at 12–16 weeks. This gradual trajectory reflects the indirect mechanism: sermorelin stimulates GH release, which then drives hepatic IGF-1 synthesis over time. Patients accustomed to the rapid IGF-1 response of exogenous GH should expect a different kinetic profile.
The clinical literature focuses primarily on individuals with documented GH insufficiency or age-related somatopause – populations where baseline IGF-1 is below the age-adjusted reference range. Use in individuals with normal IGF-1 is less well-studied, and the risk-benefit calculus is less clear. Supraphysiological IGF-1 elevation carries its own theoretical concerns, including mitogenic signaling. This is a question best addressed with a physician who can interpret baseline and follow-up laboratory values in context.
Some practitioners report a gradual attenuation of response with continuous daily administration, hypothesizing mild GHRHR downregulation. This is the rationale behind cycling protocols – typically 5 days on, 2 days off, or periodic breaks of several weeks. The evidence for cycling as a strategy to preserve responsiveness is largely empirical rather than derived from controlled trials. What the literature does confirm is that somatotroph reserve itself declines with age, meaning the ceiling of sermorelin’s effect may lower over years regardless of cycling strategy.
In the same family
Further reading in the curriculum.
Sourcing · Independently verified
When you're ready, source thoughtfully.